E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Ocular Physiological Phenomena [G14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
General objective: To evaluate the changes produced, both clinically and biochemically and cytologically, by the topical treatment with PRGF on the ocular surface in patients with glaucoma chronically exposed to ocular hypotensive drugs. Main objective:To evaluate the changes in tear osmolarity produced after topical treatment with PRGF. |
Objetivo general: Evaluar los cambios producidos, tanto a nivel clínico como bioquímico y citológico, por el tratamiento tópico con PRGF sobre la superficie ocular en pacientes con glaucoma expuestos crónicamente a fármacos hipotensores oculares. Objetivo principal: Evaluar los cambios en la osmolaridad de la lágrima producidos tras el tratamiento tópico con PRGF. |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate conjunctival clinical and cytological changes produced after topical treatment with PRGF -To evaluate the clinical and biochemical changes of the lacrimal film produced after the topical treatment of PRGF -To evaluate changes in symptomatology perceived by the patient after topical treatment with PRGF and changes in their quality of life. -To evaluate the safety of topical treatment with PGRF in patients with Glaucoma under treatment with ocular hypotensive drugs. |
-Evaluar los cambios clínicos y citológicos conjuntivales producidos tras el tratamiento tópico con PRGF -Evaluar los cambios clínicos y bioquímicos de la película lagrimal producidos tras el tratamiento tópico de PRGF -Evaluar los cambios en la sintomatología percibidos por el paciente tras el tratamiento tópico con PRGF y los cambios en su calidad de vida. -Evaluar la seguridad del tratamiento tópico con PGRF en pacientes con Glaucoma en tratamiento con fármacos hipotensores oculares. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients of legal age and diagnosed with glaucoma who are in treatment with at least two ocular hypotensive drugs (3 drops / day) without preservatives for at least the last two years and who consent to participate in the study. |
Pacientes mayores de edad y diagnosticados de glaucoma que se encuentren en tratamiento como mínimo con dos fármacos hipotensores oculares (3 gotas/día) sin conservantes durante, al menos, los dos últimos años y que den su consentimiento a participar en el estudio. |
|
E.4 | Principal exclusion criteria |
Pathology of the ocular surface other than toxicity by hypotensive drugs; previous ocular surface surgeries; treatments with topical blood products in the last 6 months, women of childbearing age with gestational desire, pregnant and lactating; serious adverse events during the study. |
Patología de superficie ocular diferente a toxicidad por fármacos hipotensores; cirugías de superficie ocular previas; tratamientos con hemoderivados tópicos en los últimos 6 meses, mujeres en edad fértil con deseo gestacional, gestantes y lactantes; acontecimientos adversos graves durante el estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Tear osmolarity |
Osmolaridad de la lágrima |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Two and four months after the start of treatment |
A los dos y cuatro meses de iniciado el tratamiento |
|
E.5.2 | Secondary end point(s) |
-Symptoms of ocular surface pathology: It will be evaluated through the validated Ocular Surface Disease Index (OSDI ©) questionnaire. - Clinical signs of ocular surface pathology: corneo-conjunctival staining using fluorescein and evaluating according to Oxford scale, Lacrimal Tear Time (BUT) under slit lamp and fluorescein staining, measurement of lacrimal production by Schirmer test. - Cytological parameters of the conjunctiva, including the classification of Nelson and evaluating the presence and density of goblet cells. - Biochemical parameters of the tear film: The presence of proinflammatory cytokines in the tear (IFN gamma, TNF alpha, TGF beta, IL-2, IL-6, IL-17, IL-8, IL-13) will be analyzed. -Quality of life related to Vision: Validated Questionnaire National Eye Institute Visual Functioning Questionnaire-25 (VQ-25). -Adverse events. |
-Síntomas de patología de superficie ocular: Se evaluará mediante el cuestionario validado Ocular Surface Disease Index (OSDI©). -Signos clínicos de patología de superficie ocular: Tinción corneo-conjuntival utilizando fluoresceína y evaluando según escala de Oxford, Tiempo de Rotura Lagrimal (BUT) bajo lámpara de hendidura y tinción con fluoresceína, medición de la producción lagrimal mediante test de Schirmer. -Parámetros citológicos de la conjuntiva, incluyendo la clasificación de Nelson y evaluando la presencia y densidad de células caliciformes. -Parámetros bioquímicos de la película lagrimal: Se analizará la presencia de citoquinas proinflamatorias en la lágrima (IFN gamma,TNF alfa,TGF beta, IL-2, IL-6, IL-17, IL-8, IL-13). -Calidad de vida relacionada con la Visión: Cuestionario validado National Eye Institute Visual Functioning Questionnaire-25 (VQ-25). -Eventos adversos. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Two and four months after the start of treatment |
A los dos y cuatro meses de iniciado el tratamiento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | |